Sutent for chodrosarcoma – pro
Chondrosarcoma can be viewed as a subtype of soft tissue sarcoma, as argued by the appeal, and this case is extraskeletal, which imeans not in the bone, straightening this argument. A case study of 10 patients with chondrosarcoma concluded that there is a therapeutic activity of sunitinib in Extraskeleta Myxoid chondrosarcoma. There are other case series that report the same findings. Reference by Stachiotti et al says: “Extraskeletal myxoid chondrosarcoma (EMCS) is a rare soft tissue sarcoma of uncertain differentiation…”
Since the classification of chondrosarcoma is the same as soft tissue sarcoma, it would be covered by the policy.
There was a clinical trial, now closed, that does NOT include chonddrosarcoma, Sunitinib in Certain Subtypes of Soft Tissue Sarcomas, for: “Patients with unresectable or metastatic angiosarcoma, epithelioid sarcoma-like hemangioendothelioma and Kaposi’s sarcoma, either receiving Sunitinib as first-line therapy or failure after no more than 2 prior chemotherapy regimens.
S Stacchiotti et al, Activity of Sunitinib in Extraskeletal Myxoid Chondrosarcoma. Eur J Cancer . 2014 Jun;50(9):1657-64.